Nimbus Synergies, a venture capital firm investing in companies using technology to improve outcomes, increase efficiencies, and lower costs in healthcare, is pleased to announce the appointment of Wendy Hurlburt and Bree Stanlake to its Board of Directors. These appointments mark a pivotal step in Nimbus’ evolution to become Canada’s leading health technology venture investment platform.
“We’re thrilled to welcome Wendy and Bree to our Board,” said Jason Robertson, Managing Partner at Nimbus Synergies. “Wendy brings deep financial and life sciences expertise, while Bree offers critical operational and entrepreneurial experience. Together, they bring exceptional value as we enter our next phase of growth.”
Proven Leaders Joining at a Pivotal Time
Wendy Hurlburt is a nationally recognized leader in life sciences and an advocate for collaboration across business, academia, and government. As President and CEO of Life Sciences BC, she leads a not-for-profit, non-government, industry association representing British Columbia’s life sciences community. Her prior executive roles at global organizations such as Johnson & Johnson, including as a senior leader at Lifescan, and her experience as CFO for multiple organizations highlight her deep expertise in financial stewardship, regulatory compliance, and strategic planning. In recognition of this, Wendy will also serve as Chair of Nimbus’ Finance Committee. “I am thrilled to join Nimbus Synergies at this exciting time,” said Hurlburt. “Throughout my career, I’ve been committed to advancing life sciences and medtech innovation and I look forward to contributing my experience and network to support Nimbus’ ambitious mission.”
Bree Stanlake is a seasoned and recognized executive leading growth and innovation at top-tier consumer and retail brands, including Reigning Champ, lululemon athletica, and ARITZIA. She currently serves as Vancouver Site Director for Creative Destruction Lab (CDL), where she supports early-stage ventures through strategic growth and commercialization. Bree’s expertise in navigating fast-paced, competitive markets will be instrumental as Nimbus continues to support ambitious health tech companies through a dynamic healthcare ecosystem. “Nimbus’ commitment to advancing Canada’s health tech sector through critical early-stage investment aligns deeply with my passion for innovation,” said Stanlake. “I’m excited to contribute to its continued success and support the next generation of impactful founders improving the world.”
A Diverse Board for a Transformative Future
The appointments of Wendy and Bree also mark a meaningful milestone in Nimbus’ commitment to board diversity, with women now comprising the majority of its directors. Their complementary skill sets and fresh perspectives will help guide Nimbus’ strategy in an evolving health tech landscape.
At the same time, Nimbus announces the retirement of David Porte from its Board. A champion of Nimbus and a long-standing advocate for innovation through Discovery Parks, David played a foundational role in the firm’s formation, growth, and success. “David’s guidance has been instrumental to our success and I want to recognize, honour, and thank David Porte for his invaluable contributions to Discovery Parks and Nimbus over the many years,” said Robertson. “His legacy lives on in the strength of our platform and the impact we continue to make.”
About Nimbus Synergies
Nimbus Synergies invests in early-stage companies using technology to improve health outcomes, increase system efficiency, and reduce costs in healthcare. Based in Vancouver, Canada, Nimbus partners with entrepreneurs driving innovation throughout the health tech ecosystem. Nimbus is positively impacting healthcare through its leadership as investor, partner, and mentor. For more information, please visit us at https://nimbusinc.vc/ or email us at info@nimbusinc.vc.